PT1115391E - Quimioterapia do cancro com acetildinalina em combinacao com gemcitabina capecitabina ou cisplatina - Google Patents

Quimioterapia do cancro com acetildinalina em combinacao com gemcitabina capecitabina ou cisplatina

Info

Publication number: PT1115391E
Authority: PT; Portugal
Prior art keywords: acetydidalin; cisplatin; chemotherapy; cancer; combination
Prior art date: 1998-09-25

Application number

PT99935442T

Other languages

English (en)

Inventor

William Richard Grove

Wayne Daniel Klohs

Ronald Lynn Merriman

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-25

Filing date

1999-07-08

Publication date

2003-02-28

1999-07-08 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2003-02-28 Publication of PT1115391E publication Critical patent/PT1115391E/pt

Links

GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 title 1
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
229960004117 capecitabine Drugs 0.000 title 1
238000002512 chemotherapy Methods 0.000 title 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title 1
229960004316 cisplatin Drugs 0.000 title 1
229960005277 gemcitabine Drugs 0.000 title 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

PT99935442T 1998-09-25 1999-07-08 Quimioterapia do cancro com acetildinalina em combinacao com gemcitabina capecitabina ou cisplatina PT1115391E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10180998P	1998-09-25	1998-09-25

Publications (1)

Publication Number	Publication Date
PT1115391E true PT1115391E (pt)	2003-02-28

Family

ID=22286531

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT99935442T PT1115391E (pt)	1998-09-25	1999-07-08	Quimioterapia do cancro com acetildinalina em combinacao com gemcitabina capecitabina ou cisplatina

Country Status (34)

Country	Link
US (3)	US6469058B1 (pt)
EP (1)	EP1115391B1 (pt)
JP (1)	JP2002525320A (pt)
KR (1)	KR20010075348A (pt)
CN (1)	CN1319009A (pt)
AP (1)	AP2001002109A0 (pt)
AT (1)	ATE225655T1 (pt)
AU (1)	AU762079B2 (pt)
BG (1)	BG105470A (pt)
BR (1)	BR9913952A (pt)
CA (1)	CA2342981A1 (pt)
CZ (1)	CZ2001905A3 (pt)
DE (1)	DE69903458T2 (pt)
DK (1)	DK1115391T3 (pt)
EA (1)	EA200100369A1 (pt)
EE (1)	EE200100187A (pt)
ES (1)	ES2185378T3 (pt)
GE (1)	GEP20043199B (pt)
HK (1)	HK1040190A1 (pt)
HR (1)	HRP20010225B1 (pt)
HU (1)	HUP0103640A3 (pt)
ID (1)	ID30046A (pt)
IL (1)	IL141951A0 (pt)
IS (1)	IS5888A (pt)
NO (1)	NO20011493L (pt)
NZ (1)	NZ510504A (pt)
OA (1)	OA11659A (pt)
PL (1)	PL348673A1 (pt)
PT (1)	PT1115391E (pt)
SK (1)	SK3602001A3 (pt)
TR (1)	TR200100859T2 (pt)
WO (1)	WO2000018393A1 (pt)
YU (1)	YU22401A (pt)
ZA (1)	ZA200102233B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR200100859T2 (tr) *	1998-09-25	2001-08-21	Warner-Lambert Company	Asetildinalin ve gemsitabin, kapesitabin veya cisplatin kombinasyonu ile kanser kemoterapisi
CZ20022216A3 (cs) *	2001-07-02	2003-05-14	Warner-Lambert Company	Kombinační chemoterapie
CA2383259A1 (en)	2002-04-23	2003-10-23	Celator Technologies Inc.	Synergistic compositions
US20080075762A1 (en) *	2001-10-03	2008-03-27	Paul Tardi	Compositions for delivery of drug combinations
US7850990B2 (en) *	2001-10-03	2010-12-14	Celator Pharmaceuticals, Inc.	Compositions for delivery of drug combinations
US20040132825A1 (en) *	2002-03-04	2004-07-08	Bacopoulos Nicholas G.	Methods of treating cancer with HDAC inhibitors
US7456219B2 (en) *	2002-03-04	2008-11-25	Merck Hdac Research, Llc	Polymorphs of suberoylanilide hydroxamic acid
RU2320331C2 (ru) *	2002-03-04	2008-03-27	МЕРК ЭйчДиЭйСи Рисерч, ЛЛС.	Способ индукции конечной дифференцировки
EP1501489A4 (en) *	2002-04-15	2007-11-21	Sloan Kettering Inst Cancer	COMBINATION THERAPY FOR THE TREATMENT OF CANCER
US8026216B2 (en)	2002-10-24	2011-09-27	Spectrum Pharmaceuticals, Inc.	Methods and compositions for contributing to the treatment of cancers
US20070032422A1 (en)	2002-10-24	2007-02-08	Spectrum Pharmaceuticals, Inc.	Methods, compositions and articles of manufacture for contributing to the treatment of cancers
GB0226434D0 (en) *	2002-11-13	2002-12-18	Astrazeneca Ab	Combination product
WO2004045617A1 (en) *	2002-11-15	2004-06-03	Warner-Lambert Company Llc	Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
WO2005000266A2 (en) *	2003-05-22	2005-01-06	Neopharm, Inc.	Liposomal formulations comprising a combination of two or more active agents
PE20050206A1 (es) *	2003-05-26	2005-03-26	Schering Ag	Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
CN100431606C (zh) *	2004-11-22	2008-11-12	山东蓝金生物工程有限公司	一种抗癌药物组合物
US7957507B2 (en)	2005-02-28	2011-06-07	Cadman Patrick F	Method and apparatus for modulating a radiation beam
CN100443081C (zh) *	2005-04-05	2008-12-17	吴一心	木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
US8232535B2 (en)	2005-05-10	2012-07-31	Tomotherapy Incorporated	System and method of treating a patient with radiation therapy
CA2616304A1 (en)	2005-07-22	2007-02-01	Tomotherapy Incorporated	System and method of delivering radiation therapy to a moving region of interest
CA2616136A1 (en)	2005-07-22	2007-02-01	Tomotherapy Incorporated	System and method of evaluating dose delivered by a radiation therapy system
ATE507879T1 (de)	2005-07-22	2011-05-15	Tomotherapy Inc	System zur verabreichung einer strahlentherapie auf ein sich bewegendes zielgebiet
US8442287B2 (en)	2005-07-22	2013-05-14	Tomotherapy Incorporated	Method and system for evaluating quality assurance criteria in delivery of a treatment plan
CA2616301A1 (en) *	2005-07-22	2007-02-01	Tomotherapy Incorporated	Method and system for evaluating delivered dose
KR20080049716A (ko) *	2005-07-22	2008-06-04	토모테라피 인코포레이티드	치료 계획의 전달과 관련된 퀄리티 보증 기준을 평가하는방법 및 시스템
WO2007014090A2 (en)	2005-07-23	2007-02-01	Tomotherapy Incorporated	Radiation therapy imaging and delivery utilizing coordinated motion of gantry and couch
WO2008027839A1 (en) *	2006-08-31	2008-03-06	Spectrum Pharmaceuticals, Inc.	Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
CN104689336A (zh) *	2008-01-28	2015-06-10	那野伽利阿株式会社	医药组合物或组合剂
FR2937867B1 (fr) *	2008-11-03	2011-03-04	Biorebus	Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
ES2593088T3 (es)	2009-04-06	2016-12-05	Otsuka Pharmaceutical Co., Ltd.	Derivados de (2'-Desoxi-Ribofuranosil)-1,3,4,7-Tetrahidro-(1,3)Diazepin-2-ona para Tratamiento de Cáncer
US8729130B2 (en)	2011-07-01	2014-05-20	The Broad Institute, Inc.	Methods of using novel solid forms of tacedinaline
WO2012003413A1 (en) *	2010-06-30	2012-01-05	The Broad Institute, Inc.	Novel solid forms of tacedinaline
US9308235B2 (en)	2012-05-09	2016-04-12	Spectrum Pharmaceuticals, Inc.	Treatment of primary and metastatic carcinoma
EP2711007A1 (en)	2012-09-19	2014-03-26	Institut Univ. de Ciència i Tecnologia, S.A.	4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en)	2012-09-19	2014-03-26	Institut Univ. de Ciència i Tecnologia, S.A.	N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711009A1 (en)	2012-09-19	2014-03-26	Institut Univ. de Ciència i Tecnologia, S.A.	Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
CN105027227B (zh)	2013-02-26	2017-09-08	安科锐公司	电磁致动的多叶准直器
US10189797B2 (en) *	2015-12-30	2019-01-29	Duke University	Chemical modulators of immune checkpoints and therapeutic use
US11987579B2 (en)	2018-07-30	2024-05-21	Duke University	Niclosamide analogues and therapeutic use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5562925A (en) *	1970-04-20	1996-10-08	Research Corporation Tech. Inc.	Anti-tumor method
NZ219974A (en) *	1986-04-22	1989-08-29	Goedecke Ag	N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
AU671491B2 (en) *	1992-12-18	1996-08-29	F. Hoffmann-La Roche Ag	N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
AU6878198A (en)	1997-04-24	1998-11-13	Warner-Lambert Company	Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma
US5972986A (en) *	1997-10-14	1999-10-26	G.D. Searle & Co.	Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
TR200100859T2 (tr) *	1998-09-25	2001-08-21	Warner-Lambert Company	Asetildinalin ve gemsitabin, kapesitabin veya cisplatin kombinasyonu ile kanser kemoterapisi

1999
- 1999-07-08 TR TR2001/00859T patent/TR200100859T2/xx unknown
- 1999-07-08 CN CN99811320A patent/CN1319009A/zh active Pending
- 1999-07-08 PL PL99348673A patent/PL348673A1/xx not_active Application Discontinuation
- 1999-07-08 ID IDW20010901A patent/ID30046A/id unknown
- 1999-07-08 DK DK99935442T patent/DK1115391T3/da active
- 1999-07-08 IL IL14195199A patent/IL141951A0/xx unknown
- 1999-07-08 OA OA1200100078A patent/OA11659A/en unknown
- 1999-07-08 EP EP99935442A patent/EP1115391B1/en not_active Expired - Lifetime
- 1999-07-08 YU YU22401A patent/YU22401A/sh unknown
- 1999-07-08 PT PT99935442T patent/PT1115391E/pt unknown
- 1999-07-08 SK SK360-2001A patent/SK3602001A3/sk unknown
- 1999-07-08 JP JP2000571912A patent/JP2002525320A/ja active Pending
- 1999-07-08 HU HU0103640A patent/HUP0103640A3/hu unknown
- 1999-07-08 CZ CZ2001905A patent/CZ2001905A3/cs unknown
- 1999-07-08 WO PCT/US1999/015386 patent/WO2000018393A1/en not_active Application Discontinuation
- 1999-07-08 KR KR1020017003794A patent/KR20010075348A/ko not_active Application Discontinuation
- 1999-07-08 GE GEAP19995872A patent/GEP20043199B/en unknown
- 1999-07-08 CA CA002342981A patent/CA2342981A1/en not_active Abandoned
- 1999-07-08 BR BR9913952-9A patent/BR9913952A/pt not_active IP Right Cessation
- 1999-07-08 DE DE69903458T patent/DE69903458T2/de not_active Expired - Fee Related
- 1999-07-08 AU AU50921/99A patent/AU762079B2/en not_active Ceased
- 1999-07-08 US US09/744,130 patent/US6469058B1/en not_active Expired - Fee Related
- 1999-07-08 NZ NZ510504A patent/NZ510504A/en unknown
- 1999-07-08 AP APAP/P/2001/002109A patent/AP2001002109A0/en unknown
- 1999-07-08 ES ES99935442T patent/ES2185378T3/es not_active Expired - Lifetime
- 1999-07-08 AT AT99935442T patent/ATE225655T1/de not_active IP Right Cessation
- 1999-07-08 EA EA200100369A patent/EA200100369A1/ru unknown
- 1999-07-08 EE EEP200100187A patent/EE200100187A/xx unknown
2001
- 2001-03-14 IS IS5888A patent/IS5888A/is unknown
- 2001-03-16 ZA ZA200102233A patent/ZA200102233B/en unknown
- 2001-03-23 NO NO20011493A patent/NO20011493L/no not_active Application Discontinuation
- 2001-03-23 HR HR20010225A patent/HRP20010225B1/xx not_active Application Discontinuation
- 2001-04-25 BG BG105470A patent/BG105470A/xx unknown
2002
- 2002-03-01 HK HK02101589.3A patent/HK1040190A1/zh unknown
- 2002-10-08 US US10/184,309 patent/US20030170300A1/en not_active Abandoned
- 2002-10-09 US US10/185,221 patent/US20030086965A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1115391B1 (en)	2002-10-09
ES2185378T3 (es)	2003-04-16
US6469058B1 (en)	2002-10-22
PL348673A1 (en)	2002-06-03
NO20011493D0 (no)	2001-03-23
AP2001002109A0 (en)	2001-03-31
ZA200102233B (en)	2002-06-18
GEP20043199B (en)	2004-03-25
DE69903458D1 (de)	2002-11-14
OA11659A (en)	2004-12-08
BR9913952A (pt)	2001-06-12
EA200100369A1 (ru)	2001-10-22
US20030086965A1 (en)	2003-05-08
WO2000018393A1 (en)	2000-04-06
TR200100859T2 (tr)	2001-08-21
CZ2001905A3 (cs)	2001-08-15
NZ510504A (en)	2003-09-26
HK1040190A1 (zh)	2002-05-31
ID30046A (id)	2001-11-01
DK1115391T3 (da)	2003-02-10
US20030170300A1 (en)	2003-09-11
AU762079B2 (en)	2003-06-19
CA2342981A1 (en)	2000-04-06
EP1115391A1 (en)	2001-07-18
HRP20010225B1 (en)	2004-10-31
JP2002525320A (ja)	2002-08-13
NO20011493L (no)	2001-05-23
DE69903458T2 (de)	2003-07-10
IS5888A (is)	2001-03-14
AU5092199A (en)	2000-04-17
BG105470A (en)	2001-12-29
HUP0103640A2 (en)	2002-06-29
ATE225655T1 (de)	2002-10-15
EE200100187A (et)	2002-08-15
HUP0103640A3 (en)	2003-01-28
IL141951A0 (en)	2002-03-10
HRP20010225A2 (en)	2002-04-30
KR20010075348A (ko)	2001-08-09
YU22401A (sh)	2004-03-12
CN1319009A (zh)	2001-10-24
SK3602001A3 (en)	2002-07-02

Publication	Publication Date	Title
PT1115391E (pt)	2003-02-28	Quimioterapia do cancro com acetildinalina em combinacao com gemcitabina capecitabina ou cisplatina
NO20006520D0 (no)	2000-12-20	Adenosinderivater
PT1053060E (pt)	2005-04-29	Queimador de oxigenio-combustivel com baixa taxa de combustao
ATE223401T1 (de)	2002-09-15	Dihydropyrimidine
PT1114031E (pt)	2005-09-30	4-carboxiamino-1,2,3,4-tetradhiroquinolinas substituidas em posicao 2
DE69818798D1 (de)	2003-11-13	Hochgeschwindige Montgomerywert-Berechnung
NO20013099L (no)	2001-08-20	Kombinasjonskjemoterapi
NO990053D0 (no)	1999-01-07	Fresstyring med orienterings- og dybdebestemmelsesevne
DK1070402T3 (da)	2009-04-14	Forbedringer angående sikkerhed i datakonferencer
DE69806025T2 (de)	2003-02-06	Krawatte mit verdeckten taschen
DE69912148D1 (de)	2003-11-20	Verbesserungen in oder hinsichtlich von vdsl übertragungssystemen
SI1115391T1 (en)	2003-02-28	Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
FR2761273B3 (fr)	1999-04-02	Planche de glisse
FR2779658B1 (fr)	2000-09-08	Planche de glisse
GB2339813B (en)	2000-08-09	Improvements in or relating to borehole logging
BR9705827A (pt)	1999-06-29	Aperfeiçoamento em evaporador com duas vias
BR7700597U (pt)	1998-11-17	Disposição introduzida em port es automáticos com travas de segurança
BR9600627A (pt)	1997-12-30	Aperfeiçoamento introduzido em fechadura eletrônica com abertura retardada
BR7800131U (pt)	1999-08-10	Disposição introduzida em fogos de artifícios do tipo rojão
BR7502444U (pt)	1996-03-26	Disposiçao introduzida em ducha eletrônica blindada
SE9804412D0 (sv)	1998-12-18	Handske med nabbar
BR7501416U (pt)	1997-09-16	Tijolo furado em solo-cimento
BR7602108U (pt)	1998-05-26	Disposição em convites
ID17884A (id)	1998-02-05	Nukleosida-nukleosida pirimidina
SE9800872D0 (sv)	1998-03-17	Sekretesslåda låsbar RETURA